Three Indomitable Shares to Invest in by 2025
In the realm of investing, some stocks may seem to be teetering on the edge of a potential decline, while others boast such strong business prospects that they appear virtually unstoppable. Three of our esteemed contributors at Our Website have identified three such healthcare stocks that they believe are destined for greatness: Eli Lilly (LLY), Intuitive Surgical (ISRG), and Vertex Pharmaceuticals (VRTX).
Eli Lilly: A Pharmaceutical Giant with Unmatched Potential
Dave Jagielski, Our Website's resident Lilly expert, maintains that despite its recent downslide, Eli Lilly's stock still has plenty of room to grow. The primary drivers behind this projected rise? The pharmaceutical giant's rapidly expanding GLP-1 drugs, Mounjaro and Zepbound.
Mounjaro, a diabetes treatment, and Zepbound, the company's recently approved weight loss drug, combined to rake in just over $4.4 billion in sales during Lilly's last quarter – an impressive figure considering these drugs are still in their early growth stages. The medications, powered by the active ingredient tirzepatide, helped patients lose an average of 26.6% of their body weight over an 84-week period in clinical trials. This groundbreaking success has catapulted Eli Lilly's stock into the spotlight and earned the company's shares a well-deserved bullish reputation.
As Lilly continues to develop oral drugs and other weight loss treatments, even more growth opportunities await. While the company is currently trading at 35 times next year's estimated future profits, Jagielski still sees it as an excellent long-term buy. It's a recipe for success that any growth-focused investor should consider adding to their portfolio.
Intuitive Surgical: The Da Vinci of Medical Device Stocks
The trajectory of Intuitive Surgical's success is a remarkable one. The pioneer of robotic surgery has performed nearly 17 million procedures to date using its da Vinci robotic surgical system. Predictably, this medical device powerhouse has been one of the top performers in the industry. Its shares have skyrocketed by more than 28,870% since its 2000 IPO, and in the past 12 months alone, the stock has jumped close to 60%.
Keith Speights, Our Website's medical device maven, is bullish on Intuitive Surgical's long-term growth prospects. The company projects that worldwide procedure growth will be between 13% and 16% this year, with the upper end of the guidance range reflecting some current challenges, such as uncertainty in China and physician strikes in South Korea. Still, Speights is confident that Intuitive Surgical will not only maintain its market dominance but also expand its share of the vast robotic surgery market, which remains largely untapped. The company is poised to unlock even more growth opportunities as populations age and its technology continues to evolve.
Vertex Pharmaceuticals: An Innovative Powerhouse with a Growth Mindset
Vertex Pharmaceuticals, a biotech firm that has cornered the market for treating cystic fibrosis (CF), is a powerhouse of innovation. Its success with CF therapies has driven robust revenue and earnings, making it a reliable choice for patient investors.
Earlier this year, Vertex's shares took a tumble following disappointing Phase 2 results for an investigational pain medicine. However, Prosper Junior Bakiny, Our Website's biotech analyst, sees this dip as an opportunity to invest in the company, which boasts a proven track record of innovation and a diverse pipeline of drug development projects. Vertex is currently working on late-stage programs and has several earlier-stage projects underway. With a successful track record of developing life-changing treatments for CF, the company is well-positioned to remain a formidable force in the biotech industry.
Integrating Enrichment Data
Here's how the enrichment data can be seamlessly integrated into the rewritten article:
According to recent financial projections, Eli Lilly anticipates revenue between $58.0 billion and $61.0 billion for 2025, representing a robust 32% growth at the midpoint from its expected 2024 revenue [1]. The company expects to earn strong revenue growth from new medicines like Jaypirca and Ebglyss and launch Mounjaro in additional international markets throughout the year [1]. Moreover, Lilly plans to significantly expand its manufacturing capacity for incretins by at least 60% during the first half of 2025 compared to the first half of 2024, ensuring it can meet customer demand [1].
Vertex Pharmaceuticals' recent year-to-date performance has been remarkably strong, with a solid 8% increase and the successful FDA approval of Journavx, an acute pain treatment [2]. The company also expects to launch three products in 2025, including Journavx, and make significant progress in its late-stage projects like APOL1, IgAN, and DPN [2]. Moreover, the MAD portion of the Phase 1/2 study of VX-522, a potential CFTR mRNA therapeutic, has been underway since early 2025, and the company has activated more than 50 treatment centers globally for CASGEVY, which is used to treat both sickle cell disease and transfusion-dependent beta thalassemia [3].
Intuitive Surgical's growth potential remains strong, as the company leads the robust robotic surgery market with its da Vinci Surgical System, which has been adopted in hospitals worldwide [1]. The company's focus on continuous innovation and comprehensive training and support programs for surgeons has ensured that more surgical procedures are performed with its systems, leading to better clinical outcomes and higher patient satisfaction [1]. As populations age and the company's technology continues to evolve, the opportunity for further growth remains immense.
These enrichment data points provide valuable context and support the strong arguments presented for each of the three unstoppable stocks. By integrating timely financial data and prospective developments, investors gain a more nuanced understanding of the market conditions and growth projections that underlie the companies' potential for outsized returns.
Dave Jagielski suggests that investors should consider Eli Lilly as a long-term buy, despite its current high valuation, due to the impressive sales of its GLP-1 drugs Mounjaro and Zepbound, and the company's plans to develop more weight loss treatments. He believes that Lilly's revenue is projected to grow significantly by 2025, driven by the success of these drugs and new medicines.
Keith Speights is optimistic about Intuitive Surgical's long-term growth prospects, citing its dominance in the robotic surgery market, which is still largely untapped, and the company's success in China and South Korea. He predicts that Intuitive Surgical will continue to maintain its market dominance and increase its share of the rapidly growing robotic surgery market, as populations age and technology evolves.
